Sector News

Analysts expect M&A frenzy to continue with deals by Pfizer, AbbVie, Valeant likely in 2015

January 7, 2015
Life sciences
Pharma M&A in 2014 hit a record-breaking $234 billion in announced acquisitions. Actavis led the pack with its $66 billion bid for Botox maker Allergan and $25 billion buyout of Forest Laboratories. But investors and analysts say 2015 could generate as many or more deals, with Pfizer, Valeant Pharmaceuticals, AbbVie and Shire expected to be in the mix.
“2014 was clearly the year of the big deal,” Rich Jeanneret, vice chair of EY’s transaction advisory services, told Bloomberg. “I think that’s going to persist in 2015 because there’s much more confidence in the M&A ecosystem.”
There also is cheap capital and the need to grow, and for the big boys, “the only real place they can find growth is through acquisition,” Jeff Stute of JPMorgan Chase & Co. told the news service.
There was a raft of deals that didn’t get done for one reason or another last year, and investors handicapping possibilities in the runup to next week’s JPMorgan Health Conference in San Francisco see each of those players as possible deal makers. Pfizer’s failed $117 billion bid last year for AstraZeneca would have dwarfed any of the buyouts that actually happened. But since it didn’t happen, and since Pfizer is still in the hunt, it is seen as the company that will define the size of the M&A action this year. Investors think Pfizer might target Actavis, or a more R&D centric player like Bristol-Myers Squibb or GlaxoSmithKline.
But other companies are also expected to be hungry for deals, investors say. Ireland’s Shire, which had been a takeover candidate of AbbVie before changes in the tax inversion laws laid that $55 billion deal to rest, is reported to already be negotiating a $4 billion plus deal with NPS Pharmaceuticals. And AbbVie may be looking to buy someone else, given that its lead product Humira goes off patent in the U.S. next year, and its other offerings, even the newly approved hepatitis C cocktail, Viekira Pak, can’t be expected to make up the $10.6 billion that Humira now earns. But AbbVie is also seen as a potential target, with some investors banking on a bid from Pfizer.
Valeant Pharmaceuticals, whose hostile takeover of Allergan was scuttled by Actavis, is also a likely buyer, but according to a Cantor Fitzgerald note, may be looking for companies in the dental field, Bloomberg said. It already owns eye care specialist Bausch + Lomb. Valeant’s effort was backed by Bill Ackman’s activist fund Pershing Square, which garnered $2.5 billion even though it backed the wrong horse. It is expected to be a catalyst in potential deals this year. It has already taken a stake in Zoetis, the animal health spinoff of Pfizer which leads in that category.
Cheap money alone may keep the M&A market active, Nasdaq biotech specialist Joe Rosenberg told Bloomberg. “We are not hearing anything that would suggest a decrease in acquirers’ M&A appetites heading into 2015.”
By Eric Palmer

Related News

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]

September 16, 2020

Takeda unveils new Boston R&D manufacturing center for cell therapy pipeline push

Life sciences

Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy […]

September 15, 2020

AstraZeneca, Oxford restart stalled COVID-19 test as Pfizer ramps up trial numbers for its vaccine

Life sciences

Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the […]